Amvuttra (vutrisiran) is a follow-up to Alnylam’s earlier RNA interference (RNAi) ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler, more patient-friendly dosing regimen.
The new therapy is given as a subcutaneous injection every three months, while Onpattro is dosed intravenously every few weeks, the same frequency as Akcea’s IV therapy Tegsedi (inotersen).